---
title: "Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: References"
description: "Reference list for the formulary evidence report on Atebrioz (zilurgisertib, INCB000928) in Fibrodysplasia ossificans progressiva. 100 cited documents."
canonical: "https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/references"
published: "2026-09-27T12:28:00-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: References

<a id="references"></a>

## 5 References

1. [Acikgoz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13135564/)
2. [Al Mukaddam et al. (2022)](https://www.tandfonline.com/doi/full/10.1080/14737167.2022.2115360)
3. [Atebrioz Prescribing Information (2026)](https://files.mirumpharma.com/atebrioz/Atebrioz-USPI-MedGuide.pdf)
4. [Baujat et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5493013/)
5. [Baujat et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13552502/)
6. [BioPharma Dive (2023)](https://www.biopharmadive.com/news/ipsen-fda-sohonos-fibrodysplasia-ossificans-progressiva/691151/)
7. [BioPharma Dive (2026)](https://www.biopharmadive.com/news/regeneron-pasatru-fda-approve-fibrodysplasia-ossificans-progressiva/828375/)
8. [BioSpace (2026)](https://www.biospace.com/fda/fda-nod-for-mirums-atebrioz-makes-3-options-for-ultra-rare-bone-disease)
9. [Bose et al. (2025)](https://ashpublications.org/blood/article/146/Supplement%201/3795/555244/The-activin-receptor-like-kinase-2-inhibitor)
10. [Botman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7972965/)
11. [Cacco et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11890112/)
12. [CADTH Pharmacoeconomic Review (2023)](https://www.ncbi.nlm.nih.gov/books/NBK596780/)
13. [CADTH Pharmacoeconomic Review Table 14 (2023)](https://www.ncbi.nlm.nih.gov/books/NBK596780/table/tr8269861151140761_ch02_t14/?report=objectonly)
14. [CADTH Pharmacoeconomic Review Table 17 (2023)](https://www.ncbi.nlm.nih.gov/books/NBK596780/table/tr8269861151140761_ch02_t17/?report=objectonly)
15. [CADTH Reimbursement Recommendation (2023)](https://www.ncbi.nlm.nih.gov/books/NBK594403/)
16. [Chen et al. (2020)](https://doi.org/10.1182/blood-2020-136138)
17. [ClinicalTrials.gov NCT04307953](https://clinicaltrials.gov/study/NCT04307953)
18. [ClinicalTrials.gov NCT04455841](https://clinicaltrials.gov/study/NCT04455841)
19. [ClinicalTrials.gov NCT04455841 results](https://clinicaltrials.gov/study/NCT04455841?tab=results)
20. [ClinicalTrials.gov NCT04582539](https://clinicaltrials.gov/study/NCT04582539)
21. [ClinicalTrials.gov NCT04582539 results](https://clinicaltrials.gov/study/NCT04582539?tab=results)
22. [ClinicalTrials.gov NCT05039515](https://clinicaltrials.gov/study/NCT05039515)
23. [ClinicalTrials.gov NCT05090891](https://clinicaltrials.gov/study/NCT05090891)
24. [ClinicalTrials.gov NCT05099445](https://clinicaltrials.gov/study/NCT05099445)
25. [ClinicalTrials.gov NCT05394116](https://clinicaltrials.gov/study/NCT05394116)
26. [ClinicalTrials.gov NCT06089616](https://clinicaltrials.gov/study/NCT06089616)
27. [ClinicalTrials.gov NCT06508021](https://clinicaltrials.gov/study/NCT06508021)
28. [Di Rocco et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10579054/)
29. [Drugs@FDA NDA 221198](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221198)
30. [European Medicines Agency (2023)](https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-sohonos-palovarotene_en.pdf)
31. [European Medicines Agency (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3119)
32. [FDA (2026)](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva)
33. [FDA approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/221198Orig1s000ltr.pdf)
34. [FDA Novel Drug Approvals (2026)](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)
35. [Fierce Pharma (2026)](https://www.fiercepharma.com/pharma/mirum-bags-fda-approval-ultra-rare-bone-lesion-disorder-heating-rivalry-regeneronns-pasatru)
36. [Gaechter et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42689548/)
37. [Harrak et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12125817/)
38. [Hatsell et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6164166/)
39. [Hino et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4687587/)
40. [Hsiao and Pacifici (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11646086/)
41. [Hsiao et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6533500/)
42. [IFOPA](https://www.ifopa.org/incb000928_trial)
43. [IFOPA Mirum FAQs (2026)](https://www.ifopa.org/mirum-fop-faqs)
44. [IFOPA zilurgisertib announcement (2026)](https://www.ifopa.org/zilurgisertib-press-release-may-2026)
45. [Incyte Corporation INCB 00928-104 protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/41/NCT04455841/Prot_000.pdf)
46. [Incyte Corporation INCB 00928-104 statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/41/NCT04455841/SAP_001.pdf)
47. [Incyte Corporation INCB 00928-105 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/39/NCT04582539/SAP_001.pdf)
48. [Incyte Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm)
49. [Incyte Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/0000879169/000087916926000056/incy-20260630.htm)
50. [International Clinical Council on FOP (2025)](https://www.iccfop.org/guidelines/3-clinical)
51. [International Clinical Council on FOP classes of medications (2024)](https://www.iccfop.org/guidelines/7-medications)
52. [International Clinical Council on FOP current treatment considerations (2024)](https://www.iccfop.org/guidelines/6-current)
53. [International Clinical Council on FOP executive summary (2025)](https://www.iccfop.org/guidelines/2-exec-summary)
54. [Ipsen (2025)](https://www.ipsen.com/press-release/ipsen-update-on-phase-ii-falkon-trial-in-patients-with-ultra-rare-bone-disease-fibrodysplasia-ossificans-progressiva-fop-3208286/)
55. [Ipsen (2026)](https://www.ipsen.com/wp-content/uploads/2026/02/Ipsen-PR_FY-2025-Results-Announcement_12022026.pdf)
56. [Kaplan et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2827822/)
57. [Kaplan et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29241828/)
58. [Kaplan et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39299836/)
59. [Kaplan et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12548730/)
60. [Keen et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11425702/)
61. [Kitterman et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16230464/)
62. [MedCity News (2026)](https://medcitynews.com/2026/09/mirum-pharmaceuticals-incyte-fda-approval-zilurgisertib-atebrioz-ultra-rare-disease-mirm-incy/)
63. [Mirum Access Plus (2026)](https://mirumaccessplus.com/)
64. [Mirum Pharmaceuticals (2026)](https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-and-Incyte-Announce-U-S--FDA-Approval-of-Atebrioz-zilurgisertib-for-Adult-and-Pediatric-Patients-with-Fibrodysplasia-Ossificans-Progressiva/default.aspx)
65. [Mirum Pharmaceuticals first-quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000036/mirm-20260506xexx991.htm)
66. [Mirum Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/0001759425/000175942526000045/mirm-20260630.htm)
67. [Mirum Pharmaceuticals PROGRESS results press release (2026)](https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-and-Incyte-Announce-Positive-Pivotal-Phase-2-Results-from-PROGRESS-Study-of-Zilurgisertib-in-Fibrodysplasia-Ossificans-Progressiva/default.aspx)
68. [Mirum Pharmaceuticals third-quarter 2026 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/04/mirum-mirm-q3-2026-earnings-call-transcript/)
69. [Mirum Pharmaceuticals third-quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000061/mirm-20261103xexx991.htm)
70. [Mohan et al. (2023)](https://ash.confex.com/ash/2023/webprogram/Paper179291.html)
71. [NICE (2025)](https://www.nice.org.uk/guidance/discontinued/gid-hst10032)
72. [NIHR Innovation Observatory (2025)](https://io.nihr.ac.uk/wp-content/uploads/2025/07/34089-Zilugisertib-for-Fibrodysplayia-Ossicans-Progressiva-V1.0-JUL2025-NON-CONF.pdf)
73. [Ortiz-Agapito et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4661157/)
74. [Pasatru Prescribing Information (2026)](https://www.regeneron.com/downloads/pasatru_fpi.pdf)
75. [Peng et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6715827/)
76. [Pignolo and Kaplan (2018)](https://pubmed.ncbi.nlm.nih.gov/28943457/)
77. [Pignolo et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4829946/)
78. [Pignolo et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6499994/)
79. [Pignolo et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32062004/)
80. [Pignolo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8340531/)
81. [Pignolo et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9014788/)
82. [Pignolo et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/36152026/)
83. [Pignolo et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36526263/)
84. [Pignolo et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/36583535/)
85. [Pignolo et al. (2026a)](https://endo2026.endocrine.org/fsPopup.asp?PresentationID=1844848&mode=presInfo)
86. [Pignolo et al. (2026b)](https://mirumpharma.com/wp-content/uploads/2026/06/QR-code-Combined-PLS-and-Poster-12June26.pdf)
87. [Pignolo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13592773/)
88. [Reuters (2026)](https://kfgo.com/2026/09/25/us-fda-approves-mirums-drug-for-rare-bone-disorder/)
89. [Shore et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16642017/)
90. [Smilde et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9156821/)
91. [Sohonos Prescribing Information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67dce406-7cc4-4d66-92de-ad18b6df0625)
92. [Swain (2026)](https://www.healio.com/news/endocrinology/20260702/novel-agent-reduces-new-ossification-lesions-in-patients-with-rare-bone-disease)
93. [Ullrich et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41256990/)
94. [Xu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12333074/)
95. [Xun et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/35264018/)
96. [Xun et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/36416749/)
97. [Yang et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11802711/)
98. [Yang et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40462754/)
99. [Yang et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856974/)
100. [Yang et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13122279/)

## Related pages
- [Atebrioz (zilurgisertib): Fibrodysplasia ossificans progressiva](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva) · [Markdown](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva.md)
- [Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: Terms and abbreviations](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/terms-and-abbreviations.md)
- [Atebrioz (zilurgisertib): Fibrodysplasia ossificans progressiva](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/executive-summary) · [Markdown](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/executive-summary.md)
- [Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: Product information and disease description](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/product-information-and-disease-description.md)
- [Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: Clinical evidence](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/clinical-evidence.md)
- [Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: Economic information and modeling report](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/economics) · [Markdown](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/economics.md)
- [Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: new drug review](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/monograph/review) · [Markdown](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/monograph/review.md)
- [Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: prevalence by geography](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/prevalence) · [Markdown](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/prevalence.md)
- [Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/cost-effectiveness-analyses.md)
- [Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: interactive budget impact model](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/budget-impact-model) · [Markdown](https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/budget-impact-model.md)
